In contrast, dual checkpoint combinations incorporating TIGIT plus PD-1 blockade with or without dual A2A/A2B inhibition, etrumadenant, improved outcomes vs PD-1 blockade alone in the randomized phase 2 ARC-7 trial of PD-L1-high, first-line metastatic NSCLC [32]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.